Dassault Systèmes in talks to buy drug trial software company for $2B - FT
Seeking Alpha ·
Dassault Systèmes ( DASTY ) is in discussions to acquire drug trial software maker ArisGlobal from Nordic Capital for about $2 billion. Talks between the parties are ongoing, according to a Financial Times report on Thursday, which cited people familiar with the matter. A deal
AI 시장 분석
Dassault Systèmes is reportedly leading a cross-Atlantic deal to acquire ArisGlobal, a maker of preclinical trial software, for approximately $20bn. The deal is currently underway, based on a report by the Financial Times, following discussions between Nordic Capital and Dassault Systèmes.
상승 영향
- Biotech — Increased demand for biotech software drives Dassault Systèmes' market share growth
- IT — Increased demand for software industry drives Dassault Systèmes' market share growth
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 35% · Bearish (Short) 65%
405 participants
Related News
- Cycurion receives delisting determination letter from Nasdaq
- Ohmyhome falls after Nasdaq flags minimum bid price deficiency
- SOLAI trading suspended as NYSE starts delisting process
- Beyond the Nvidia boom: portfolio manager likes AI stocks TSMC, ASML
- Wise Group plc reports Q1 results
- Intuitive Surgical falls despite better-than-expected Q2 results